47 results about "Presenile dementia" patented technology

The invention relates to a novel scutellarin aglycon 4 (1)-position carbamate derivant (1), a preparation method and the application thereof. A pharmacological experiment proves that the compounds have obvious inhibitory activity of acetylcholinesterase and have protective effect with different degrees on PC12 cell trauma induced by H2O2, so the compounds can be used for preparing the drugs for treating neurodegenerative diseases such as vascular dementia, AD (presenile dementia), etc.

The invention relates to a nutrition even blend oil which contains seaweed oil. The nutrition even blend oil uses plant grease such as peanut oil and flax seed oil as the material oil, uses seaweed oil as the alloyed oil, uses fat fusible tea polyphenol and vitamin E as the anti-crawl oxidant. The accession volume can be calculated according to the physiology and the nutrition need of different people and the fatty acid content of the oil; each 100 gram finished blend oil contains: SFA 12 to 18 grams, MUFA 39 to 46 grams, Omega-6 PUFA 31 to 38 grams, Omega-3 PUFA 5 to 9 grams; wherein, Omega-3 LCPUFA 0.1 to 5.0 grams, DHA:(DPA+EPA) 0.25 to 10:1, DHA:EPA 4:1 to 60:1, or DHA:DPA 2:1 to 10:1, no EPA, or HAD without DPA and EPA. The blend oil has the functions of promoting the brain growth and defending the short sight and the presenile dementia and reducing the cerebrovascular disease.

A mixture for preventing and treating the free radical oxidizing damage of biologic cells, such as presenile dementia, Parkinson's disease, cerebrosclerosis, apoplexy, cardiovascular disease, tumor, etc is prepared from VC, VE and melatonin.

The invention discloses a compound for treating and relieving neurodegenerative diseases and relates to the technical field of medicine. The compound is an artemisinin derivative, and the artemisinin derivative comprises artemether, arteether, artesunatum, dihydroartemisinin and pharmaceutically acceptable minor ingredients. The compound for treating and relieving neurodegenerative diseases can treat presenile dementia, Parkinson syndrome and Huntington's diseases, the toxic and side effect is low, the cost is low, no drug resistance is produced, the compound can be taken for a long term and the practicability is strong.

The invention discloses a novel 2,5-dyhydroxy-p-phthalamide compound (I) and pharmaceutically acceptable salts thereof, a preparation method of the compound and application in preparing medicine treating and/or preventing nervous system related diseases. The diseases include but not limited to the vascular dementia, presenile dementia, Parkinson's disease, Huntington's disease, HIV related Alzheimer disease, nerve injuries caused by the traumatic brain injury and other diseases. The formula is defined in the description.

The invention provides a substitute five membered heterocyclic compound represented by the following formula, and salt, ester, solvate and metal composition which are all accepted by pharmacy or a prodrug having the same biological activity. The invention also provides a purpose of the compound as a glucagon-like peptide-1 receptor (GLP-1R) signal transduction positive modulator and an application for preventing and/or curing metabolic diseases (including but not being limited to type-2 diabetes, insulin resistance and adiposity, and the like), angiocardiopathy and neurodegenerative diseases (such as Alzheimer's disease, AD) also called presenile dementia, and the like.

The invention discloses a medicinal composition used for treating or preventing cerebrovascular disease and related diseases. The composition comprises the following components in parts by weight: 1-50 parts of DHA (docosahexaenoic acid), 1-50 parts ofbreviscapine, 20-50 parts of and 1-10 parts of hirudin. The composition also comprises effective amount of human fat stem cell which is taken as a carrier for the medicinal composition, thus treatment medicine smoothly penetrates through a blood brain barrier, and the effect of targeted treatment on the cerebrovascular disease and related diseases is achieved. The medicinal composition disclosed by the invention can effectively improve diseases such as attack, infarction and embolism which are caused by ischemia of the brain, can effectively inhibit thrombus from being formed in human body and has good curative effect on senile dementia caused by the cerebrovascular disease, namely presenile dementia.

The invention provides a novel herbal formulation used to improve the memory and in treatment of senile and presenile dementia as a brain tonic. Formulation(s) comprises of alcoholic extract of Tinospora cordifolia, Centella asiatica, Withania somnifera, Mucuna pruriens and Curcuma longa. The formulation can be used as an emulsion or as a soft gelatin capsule for oral dosage forms.

The invention relates to a preparation method of key intermediate (S)-3-(1-dimethylaminoethyl)phenol of Rivastigmin for curing presenile dementia, comprising the following steps: adopting (RS)m-benzyloxy-alpha,N-dimethyl benzylamine as raw material and L-(+)-tartaric acid as resolving agent to obtain (S)m-benzyloxy-alpha,N-dimethyl benzylamine, and finally obtaining the target product (S)-3-(1-dimethylaminoethyl)phenol in the presence of aldehyde solution and Raney nickel in alcoholic solution through aminomethylation and hydrogenation by which benzyl can be removed; meanwhile, (R)m-benzyloxy-alpha,N-dimethyl benzylamine and partial (S)m-benzyloxy-alpha,N-dimethyl benzylamine in the separated mother solution are recycled and after racemizing the recycled materials in the present of basic catalyst, (RS)m-benzyloxy-alpha,N-dimethyl benzylamine can be obtained to be used as raw material for repeatedly use and separation. The method of the invention has simple process and cheap raw materials; the separated R-enantiomer can be recycled after the racemization, and compared with the prior art, the yield is greatly improved and the cost is reduced so that the preparation method is applicable to the industrial production.

The present invention belongs to the field of medical evaluation and detection technology, and is especially the construction process of Alzheimer's disease (AD) rat animal model. Rat is set in lighting environment of 10-1000 Lux light strength continuously for 1-10 weeks. The model may be used in the research of AD pathogenesis in the early stage or the disease process including beta-amyloid protein increase and congregation, skelemin Tau AD like abnormality and over phosphorylation, etc., the screening of medicine for treating AD, the evaluation of AD treating method and the research of AD pathogenesis.

The invention provides a detection method for obtaining rat sinkaline signals through Proton MR spectroscopy (<1>H MRS) and then indirectly reflecting the content of acetylcholines in a rat. The method compares the content relationship of total sinkaline and acetylcholines in a sea horse area, a striaturn area, a frontal cortex area and a somatic cortex area of the normal rat; the contents of the total sinkaline and the acetylcholines of the rat in the four brain areas have obvious relativity through double variant and linear regression analysis. As shown by the result, the rat sinkaline signals obtained through the Proton MR spectroscopy are used as the predicated value of the content of the acetylcholines in the rat, which has statistic significance. Simultaneously, loss of the acetylcholines is a very important neuropathological variation of presenile dementia, thereby the method is hopeful to be applied to noninvasive early clinical diagnosis of the presenile dementia.

The invention discloses a health egg which is oxidation resistant, preventing and curing the senile dementia, born by poultry nursed with feed stuff added with curcuma longa; adding curcuma longa of 5-1000mg per basic feed stuff for poultry or curcuma longa slag of 5-300g, with the nursing time for at least 8 days, and the curcuma longa can be added in the long run. The invention makes the function of curcuma longa and polarity egg be combined together, which makes the action of oxidation resistance and prevention and cure of the senile dementia stronger. The invention employs biological transformation technique, employs poultry laying egg as carrier, to transform the effect component in the curcuma longa into eggs through the biological enrichment function of poultry, and to realize purpose of being oxidation resistant, and preventing and curing the senile dementia.

The present invention relates to a compound-laughing gas synthase inhibitor. Said invention also provides its general formula and its preparation method, and also discloses the medicine containing said compound and its application for curing the diseases of septic shock, enteritis, rheumatoid arthritis, diabetes mellitus, cerebral ischemic injury and presenile dementia, etc.

The present invention provides a medicine for presenile dementia treatment, which takes dehydrogenation evodiamine as the active component. Studies proves that the dehydrogenation evodiamine has an inhibiting effect in notable pathological change of presenile dementia patients, which can not only reduce the senile plaque quantity of the presenile dementia, but also can reduce the phosphorylation tau protein level, therefore learning and memory impairment are dramatically improved. The medicine is an effective medicine for presenile dementia prevention and treatment.

The invention discloses traditional Chinese medicine decoction for preventing and treating presenile dementia. The traditional Chinese medicine decoction is prepared from the following traditional Chinese medicinal materials in parts by weight: 20 parts of prepared rehmannia root, 15 parts of rhizome of acorus calamus, 10 parts of radix polygoni multiflori, 25 parts of the root of red-rooted salvia, 10 parts of szechuan lovage rhizome, 12 parts of dried mature seeds of corylus avellana, 18 parts of dried mature fruit of citrullus colocynthis, 8 parts of forest frog's oviduct, 15 parts of Mongolian snakegourd root, 8 parts of Chinese thorowax root, 8 parts of oyster, 18 parts of fructus chebulae immaturus, 12 parts of all-grass of digitaria sanguinalis, 8 parts of astragalus membranaceus, 12 parts of mature coconut fruit, 5 parts of tobacco, 5 parts of sapium baccatum, 6 parts of seeds and roots of wild sword bean and 6 parts of aizoon stonecrop herb. Clinical experiment results show that the remarkable efficacy of preventing and treating presenile dementia is realized by selecting proper medicinal materials according to the ratio, and high safety and no toxic or side effects are realized.

A medicine for treating presenile dementia is just the HA-T1 which is the huperzine A derivative N-methyl-1,4-dihydropyridine-3-formate or the HA-T2 which is the huperzine A derivative N-methyl-1,2,5,6-tetrahydropyridine-3-formate. Its preparing process is also disclosed.

The present invention provides a kind of indoxyl piperidine compound. The pharmacological tests show that said kind of compound can be used as inhibitor of acetylcholin esterase, can competitively inhibit the activity of acetylcholin esterase, can delay hydrolysis of acetylcholin so as to raise the action of acetylcholin in synapsis and attain the goal of curing presenile dementia.

The present invention proposes a series of novel substituted quinoxaline 2,3-diones useful as neuroprotective agents. Also proposed are new intermediates, preparation methods and pharmaceutical compositions containing the compound. The compound is a glutamate antagonist and can be used in the treatment of stroke, cerebral ischemia, or cerebral infarction caused by thromboembolic or hemorrhagic stroke, cerebral vasospasm, hypoglycemia, cardiac arrest, status epilepticus, and peripartum asphyxia , hypoxia, Alzheimer's disease, Parkinson's disease and Huntington's disease.